Cover of The Intelligent Investor Third Edition by Benjamin Graham, Jason Zweig - Business and Economics Book

From "The Intelligent Investor Third Edition"

Author: Benjamin Graham, Jason Zweig
Publisher: HarperCollins
Year: 2024
Category: Business & Economics

🎧 Free Preview Complete

You've listened to your free 10-minute preview.
Sign up free to continue listening to the full summary.

🎧 Listen to Summary

Free 10-min Preview
0:00
Speed:
10:00 free remaining
Chapter 12: Things to Consider About Per-Share Earnings
Key Insight 3 from this chapter

The Problematic Nature of Non-GAAP Financial Reporting

Key Insight

Companies increasingly rely on non-GAAP (Generally Accepted Accounting Principles) reporting, which often excludes various items from expenses or income, creating a potentially misleading picture of profitability. These alternative figures are frequently highlighted in earnings announcements and conference calls, becoming as influential as the 'real' GAAP numbers and often tied to executive compensation. While non-GAAP numbers ideally remove unusual costs to provide a clearer view of a company's core performance and future profitability, there is a critical absence of regulatory or accounting standards governing what can be excluded and why. This grants executives significant discretion, allowing them to change metrics without warning or explanation, thereby controlling the narrative of their company's financial health.

Many companies use non-GAAP reporting to present a 'fairy tale' of their financial results, where expenses seemingly vanish and ephemeral income appears durable. Examples abound: Groupon in 2011 concocted 'adjusted consolidated segment operating income' (ACSOI) to report a 63 million dollar profit, despite a 423 million dollar GAAP loss, by excluding online marketing expenses (later mandated by the SEC to be included). In 2018, WeWork created 'community-adjusted EBITDA' to wave away sales, marketing, and administration costs, reporting 233 million dollars in non-GAAP earnings despite a 933 million dollar GAAP loss. Furthermore, pharmaceutical giants such as Bristol-Myers Squibb, Eli Lilly, and Pfizer consistently excluded portions of research and development costs for years, inflating their non-GAAP earnings by billions until regulatory pressure in 2022 prompted a change.

A common deceptive practice involves treating recurring expenses as 'non-recurring' within non-GAAP adjustments. 'Restructuring charges,' such as those for selling assets, shutting divisions, or layoffs, are often presented as one-time, yet 68 S&P 500 companies incurred them annually from 2013 to 2022, with 36 adding them back to non-GAAP income in 2022. HP Inc., for instance, took restructuring charges 10 times over 10 years, totaling nearly 5.1 billion dollars, which was an eighth of its GAAP operating profits, only to exclude them from non-GAAP operating income. Another significant, and often excluded, expense is stock-based compensation. Oracle Corporation and Salesforce, Inc. added back 15.6 billion dollars and 14.1 billion dollars, respectively, in stock-based compensation over 10 years, dramatically inflating their non-GAAP operating income. In contrast, Microsoft Corporation paid out 48.1 billion dollars in stock-based compensation over the same period but did not exclude it from its non-GAAP income, recognizing it as a normal, recurring cost of doing business. Surveys reveal widespread recognition of these issues among CFOs and analysts, with many believing such misrepresentations are used to support stock prices, meet external profit pressures, and inflate executive compensation.

📚 Continue Your Learning Journey — No Payment Required

Access the complete The Intelligent Investor Third Edition summary with audio narration, key takeaways, and actionable insights from Benjamin Graham, Jason Zweig.